S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
Most-Downgraded StocksMost-Downgraded
NASDAQ:BIIB

Biogen (BIIB) Stock Forecast, Price & News

$257.68
-1.25 (-0.48%)
(As of 09/22/2023 ET)
Compare
Today's Range
$257.09
▼
$260.72
50-Day Range
$253.30
▼
$278.40
52-Week Range
$194.45
▼
$319.76
Volume
800,827 shs
Average Volume
723,311 shs
Market Capitalization
$37.32 billion
P/E Ratio
14.03
Dividend Yield
N/A
Price Target
$325.36
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
26.3% Upside
$325.36 Price Target
Short Interest
Healthy
2.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
1.09mentions of Biogen in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$139,037 Sold Last Quarter
Proj. Earnings Growth
6.89%
From $15.25 to $16.30 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

60th out of 963 stocks

Biological Products, Except Diagnostic Industry

6th out of 158 stocks

See Top Rated MarketRank™ Stocks Here

BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Price History

BIIB Stock News Headlines

September 23, 2023 | msn.com
These companies set to benefit from sales of Biogen Alzheimer's med Leqembi
September 21, 2023 | nasdaq.com
Reata Pharma Stockholders Approve Acquisition By Biogen
September 24, 2023 | Stansberry Research (Ad)
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
September 21, 2023 | businesswire.com
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
September 20, 2023 | finance.yahoo.com
GE Healthcare: why it's still waiting on its Leqembi windfall
September 13, 2023 | finance.yahoo.com
Biogen Inc.'s (NASDAQ:BIIB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
September 12, 2023 | msn.com
Intas reportedly readying bid of up to $1B for Biogen biosimilars unit
September 12, 2023 | finance.yahoo.com
Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know
September 24, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 12, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)
September 11, 2023 | stocknews.com
3 Biotech Gainers to Consider
September 11, 2023 | seekingalpha.com
Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
September 9, 2023 | morningstar.com
Biogen Inc BIIB Stock Quote
September 8, 2023 | finance.yahoo.com
Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?
September 7, 2023 | finance.yahoo.com
The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure
September 7, 2023 | msn.com
HSBC Initiates Coverage of Biogen (BIIB) with Buy Recommendation
September 6, 2023 | msn.com
Biogen names Dr. Jane Grogan head of research effective Oct. 2
September 6, 2023 | finance.yahoo.com
Biogen Appoints Jane Grogan as Head of Research
September 6, 2023 | finance.yahoo.com
Octave Bioscience Releases Multiple Sclerosis Study in Biogen Partnership
September 5, 2023 | finance.yahoo.com
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
September 5, 2023 | seekingalpha.com
Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play
September 2, 2023 | finance.yahoo.com
Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 89% of the company
August 31, 2023 | reuters.com
Sage Therapeutics to cut 40% of jobs after depression drug setback
August 31, 2023 | msn.com
Sage Therapeutics to cut about 188 jobs after depression drug setback
August 31, 2023 | msn.com
Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch
August 31, 2023 | finance.yahoo.com
UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback
August 29, 2023 | finance.yahoo.com
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
7/25/2023
Today
9/24/2023
Next Earnings (Estimated)
10/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
CIK
875045
Web
www.biogen.com
Phone
(617) 679-2000
Fax
617-679-2617
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$325.36
High Stock Price Forecast
$381.00
Low Stock Price Forecast
$269.00
Forecasted Upside/Downside
+26.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
27 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$18.37
Trailing P/E Ratio
14.03
Forward P/E Ratio
16.90
P/E Growth
2.79
Net Income
$3.05 billion
Net Margins
26.72%
Pretax Margin
31.30%
Return on Equity
17.33%
Return on Assets
9.51%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
3.27
Quick Ratio
2.86

Sales & Book Value

Annual Sales
$10.17 billion
Price / Sales
3.67
Cash Flow
$21.51 per share
Price / Cash Flow
11.98
Book Value
$92.97 per share
Price / Book
2.77

Miscellaneous

Outstanding Shares
144,820,000
Free Float
143,954,000
Market Cap
$37.32 billion
Optionable
Optionable
Beta
0.13

Social Links

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 62)
    Pres, CEO & Director
    Comp: $487.94k
  • Mr. Michael R. McDonnell CPA (Age 59)
    Exec. VP & CFO
    Comp: $2.12M
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 66)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $2.2M
  • Dr. Ginger Gregory (Age 55)
    Exec. VP & Chief HR Officer
    Comp: $1.59M
  • Ms. Robin C. Kramer (Age 57)
    Sr. VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Sr. VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corp. Affairs
  • Mr. Adam Keeney Ph.D.
    Exec. VP & Head of Corp. Devel.
  • Ms. Alisha A. Alaimo
    Pres & Head of North America

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

27 Wall Street analysts have issued 12 month price targets for Biogen's shares. Their BIIB share price forecasts range from $269.00 to $381.00. On average, they expect the company's share price to reach $325.36 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the start of the year. Since then, BIIB stock has decreased by 6.9% and is now trading at $257.68.
View the best growth stocks for 2023 here.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our BIIB earnings forecast.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, July, 25th. The biotechnology company reported $4.02 EPS for the quarter, topping analysts' consensus estimates of $3.77 by $0.25. The biotechnology company earned $2.46 billion during the quarter, compared to analyst estimates of $2.36 billion. Biogen had a trailing twelve-month return on equity of 17.33% and a net margin of 26.72%. The company's revenue for the quarter was down 5.1% on a year-over-year basis. During the same period in the prior year, the company earned $5.25 EPS.
Read the conference call transcript.

What ETFs hold Biogen's stock?

ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and Goldman Sachs Future Health Care Equity ETF (GDOC).

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $15.00-$16.00 for the period, compared to the consensus estimate of $15.42. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.71%), State Street Corp (4.75%), Geode Capital Management LLC (2.20%), Bank Julius Baer & Co. Ltd Zurich (1.44%), Clearbridge Investments LLC (1.26%) and Northern Trust Corp (1.10%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $257.68.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $37.32 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $18.37 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -